Browsing Academic by Subject "BNT162b2"

Now showing items 1-4 of 4

    • BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. 

      Tang, Patrick; Hasan, Mohammad R; Chemaitelly, Hiam; Yassine, Hadi M; Benslimane, Fatiha M; ... more authors ( Nature Researc , 2021 , Article)
      With the global expansion of the highly transmissible SARS-CoV-2 Delta (B.1.617.2) variant, we conducted a matched test-negative case-control study to assess the real-world effectiveness of COVID-19 messenger RNA vaccines ...

    • Clinical outcomes of Pfizer-BioNTech COVID-19 vaccine in children and adolescents: A systematic review 

      Al-Qudimat, Ahmad R.; Al-Zoubi, Raed M.; Elaarag, Mai; Nashwan, Abdulqadir J.; Hamze, Afaf K.; ... more authors ( John Wiley and Sons Inc , 2022 , Article Review)
      Background & Aims: The BioNTech-Pfizer vaccine is the only vaccine offered to children among all available vaccines. However, limited evidence is available about the clinical outcomes of COVID-19 vaccines, especially among ...

    • Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. 

      Abu-Raddad, Laith J; Chemaitelly, Hiam; Butt, Adeel A ( Massachusetts Medical Society , 2021 , Other)
      The messenger RNA vaccine BNT162b2 (Pfizer–BioNTech) has 95% efficacy against coronavirus disease 2019 (Covid-19). Qatar launched a mass immunization campaign with this vaccine on December 21, 2020. As of March 31, 2021, ...

    • Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. 

      Chemaitelly, Hiam; Tang, Patrick; Hasan, Mohammad R; AlMukdad, Sawsan; Yassine, Hadi M; ... more authors ( Massachusetts Medical Society , 2021 , Article)
      Waning of vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern. The persistence of BNT162b2 (Pfizer-BioNTech) vaccine ...